Literature DB >> 26940529

Early Weight Loss during Chemoradiotherapy Has a Detrimental Impact on Outcome in NSCLC.

Karin J C Sanders1, Lizza E Hendriks2, Esther G C Troost3, Gerben P Bootsma4, Ruud M A Houben5, Annemie M W J Schols6, Anne-Marie C Dingemans2.   

Abstract

OBJECTIVES: The aim of this study was to assess the effect of early weight loss before the onset of radiation esophagitis on overall survival (OS) in patients with non-small cell lung cancer treated with concurrent chemoradiotherapy.
METHODS: Characteristics (e.g., patient weight, radiation esophagitis score, sex, World Health Organization performance status, chemotherapy dose, nodal status, and gross tumor volume) of 151 patients who received concurrent chemoradiotherapy (in 2006-2013) were retrospectively correlated with OS. Early weight loss was defined as weight loss of more than 5% between the start and third week of radiotherapy in patients whose weight was stable before treatment initiation.
RESULTS: In 17% of the patients early weight loss was observed. Median OS (95% confidence interval [CI]) was significantly shorter in the early weight loss group (OS = 13.0 months, 95% CI: 2.0-24.0) versus in the non-early weight loss group (OS = 23.0 months, 95% CI: 14.7-31.3) (hazard ratio [HR] = 1.8, 95% CI: 1.12-2.96, p = 0.017). On multivariate analysis sex (HR = 2.1, 95% CI: 1.33-3.29, p = 0.001), World Health Organization performance status (HR = 1.9, 95% CI: 1.20-2.97, p = 0.006), nodal status (HR = 2.9, 95% CI: 1.38-6.01, p = 0.005), and early weight loss (HR = 1.9, 95% CI: 1.10-3.19, p = 0.022) were associated with OS.
CONCLUSIONS: Early weight loss in patients with non-small cell lung cancer was found to be associated with worse prognosis. These data warrant further investigation into the efficacy of tailored intervention to prevent early weight loss.
Copyright © 2016 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cachexia; Non–small cell lung cancer; Survival; Weight loss

Mesh:

Year:  2016        PMID: 26940529     DOI: 10.1016/j.jtho.2016.02.013

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  11 in total

Review 1.  The Role of Malnutrition and Muscle Wasting in Advanced Lung Cancer.

Authors:  Rishi Jain; Chris Coss; Peter Whooley; Mitch Phelps; Dwight H Owen
Journal:  Curr Oncol Rep       Date:  2020-05-15       Impact factor: 5.075

2.  An analysis of the relationship between metastases and cachexia in lung cancer patients.

Authors:  Masatoshi Shiono; Kan Huang; Robert J Downey; Nikita Consul; Nicolas Villanueva; Kristen Beck; Kathleen Fenn; Donald Dietz; Takuhiro Yamaguchi; Shunsuke Kato; Chaitanya Divgi; Kevin Kalinsky; Ying Wei; Yuan Zhang; Alain C Borczuk; Akira Inoue; Balazs Halmos; Swarnali Acharyya
Journal:  Cancer Med       Date:  2016-08-03       Impact factor: 4.452

Review 3.  A critical review of recent developments in radiotherapy for non-small cell lung cancer.

Authors:  Sarah Baker; Max Dahele; Frank J Lagerwaard; Suresh Senan
Journal:  Radiat Oncol       Date:  2016-09-06       Impact factor: 3.481

4.  The applicability of a weight loss grading system in cancer cachexia: a longitudinal analysis.

Authors:  Ola Magne Vagnildhaug; David Blum; Andrew Wilcock; Peter Fayers; Florian Strasser; Vickie E Baracos; Marianne J Hjermstad; Stein Kaasa; Barry Laird; Tora S Solheim
Journal:  J Cachexia Sarcopenia Muscle       Date:  2017-06-18       Impact factor: 12.910

Review 5.  Nutritional Interventions in Cancer Cachexia: Evidence and Perspectives From Experimental Models.

Authors:  Wouter R P H van de Worp; Annemie M W J Schols; Jan Theys; Ardy van Helvoort; Ramon C J Langen
Journal:  Front Nutr       Date:  2020-12-22

6.  Early Loss of Fat Mass During Chemoradiotherapy Predicts Overall Survival in Locally Advanced Squamous Cell Carcinoma of the Lung, but Not in Locally Advanced Squamous Cell Carcinoma of the Head and Neck.

Authors:  A C H Willemsen; J H R J Degens; L W J Baijens; A-M C Dingemans; A Hoeben; F J P Hoebers; D K M De Ruysscher; A M W J Schols
Journal:  Front Nutr       Date:  2020-11-26

Review 7.  Practical implications to contemplate when considering radical therapy for stage III non-small-cell lung cancer.

Authors:  Claire L Storey; Gerard G Hanna; Alastair Greystoke
Journal:  Br J Cancer       Date:  2020-12       Impact factor: 7.640

8.  Cancer cachexia as a determinant of efficacy of first-line pembrolizumab in patients with advanced non-small cell lung cancer.

Authors:  Hironori Fujii; Ayumu Araki; Hirotoshi Iihara; Daizo Kaito; Chiemi Hirose; Motohiko Kinomura; Mizuki Yamazaki; Junki Endo; Toshiya Inui; Komei Yanase; Yuka Sasaki; Takenobu Gomyo; Chizuru Sakai; Daisuke Kawae; Yu Kitamura; Masachika Fukui; Ryo Kobayashi; Yasushi Ohno; Akio Suzuki
Journal:  Mol Clin Oncol       Date:  2022-02-24

9.  Impact of Weight Loss at Presentation on Survival in Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-TKI) Sensitive Mutant Advanced Non-small Cell Lung Cancer (NSCLC) Treated with First-line EGFR-TKI.

Authors:  Liping Lin; Juanjuan Zhao; Jiazhu Hu; Fuxi Huang; Jianjun Han; Yan He; Xiaolong Cao
Journal:  J Cancer       Date:  2018-01-01       Impact factor: 4.207

10.  Exploring the Relationship of Radiation Dose Exposed to the Length of Esophagus and Weight Loss in Patients with Lung Cancer.

Authors:  Peijin Han; Russell Hales; Pranav Lakshminarayanan; Zhi Cheng; Christen Elledge; Alex Negron; Sarah Hazell; Chen Hu; Cole Friedes; Lori Anderson; Jeffrey Hoff; Kristen Marrone; Harry Quon; Todd McNutt; K Ranh Voong
Journal:  Pract Radiat Oncol       Date:  2020-03-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.